CK 1827452

Known as: CK-1827452 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2015
01220062015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
INTRODUCTION Current available inotropic agents increase cardiac contractility, but are associated with myocardial ischemia… (More)
Is this relevant?
2015
2015
OBJECTIVES The goal of this study was to assess the safety and tolerability of omecamtiv mecarbil treatment during symptom… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Many patients with heart failure remain symptomatic and have a poor prognosis despite existing treatments. Decreases… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2011
2011
A new study in Science provides proof of the principle for directly modulating the cardiac muscle’s motor, myosin, as a… (More)
Is this relevant?
2009
2009
Cytokinetics Inc is developing CK-1827452, an agent that directly activates myosin, for use in the treatment of heart failure… (More)
Is this relevant?
2009
2009
  • Nature Reviews Drug Discovery
  • 2009
 
Is this relevant?
2008
2008
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart… (More)
  • table 1
  • figure 1
Is this relevant?
2006
2006
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart… (More)
Is this relevant?